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Background: Behçet’s Disease (BD) is an autoimmune disease mostly presenting with
recurrent oral and genital aphthosis, and uveitis. Patients are rarely refractory to
immunosuppressive treatments. Autologous hematopoietic stem cell transplantation
(aHSCT) is a standard of care in other autoimmune diseases. Some patients with BD
have been treated with aHSCT based on compassionate use.
Objectives: Evaluate the outcome of aHSCT in adult patients with BD treated in member
centers of the European Society for Blood and Marrow Transplantation (EBMT).
Methods: Adults who received aHSCT primarily for BD were identified retrospectively in
the EBMT registry and/or in published literature. Data were extracted from either medical
records of the patient or from publications.
Results: Eight out of 9 cases reported to the registry and extracted data of 2 further
patients from literature were analyzed. Four were female, median age at onset of BD was
24y (range 9-50). Median age at aHSCT was 32y (27-51). Patients had received median 4
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(2-11) previous lines of therapy (89% corticosteroids, 50% methotrexate, anti-TNFa
therapy or cyclophosphamide). All patients had active disease before mobilization.
Conditioning regimen was heterogeneous. Median follow-up was 48 months (range 6-
240). No treatment-related mortality was reported. This procedure induced complete
remission (CR) in 80%, partial remission in 10% and lack of response in 10% of the
patients. Relapse rate was 30% (2 relapses in patients in CR and 1 relapse in the patient
in PR) with panuveitis (n=1), aphthosis (n=2) and arthralgia (n=1). Six patients were in CR.
No late complications were reported.
Conclusion: aHSCT has an acceptable safety profile and represents a feasible and
relatively effective procedure in severe and conventional treatment-resistant cases of BD
and has the potential to stabilize BD in patients with life-threatening involvements.
Keywords: Behçet’s disease, autologous stem cell transplantation, efficacy, toxicity, immune reset
KEY POINTS
1) aHSCT has an acceptable safety profile and represents a
feasible and relatively effective procedure in severe and
conventional treatment-resistant cases of BD
2) aHSCT has the potential to stabilize BD in patients with life-
threatening involvements.
3) The rate of failure and relapse seems to be low.
INTRODUCTION
Behçet´s disease (BD) is a rare autoimmune disease mostly
presenting with recurrent oral and genital aphthosis, and uveitis.
Other common symptoms include gastrointestinal, vascular,
neurological and articular manifestations (1). The first
internationally agreed criteria for BD were the International
Study Group (ISG) criteria (2). They had very high specificity,
but lacked satisfactory sensitivity, missing out on a sizable subset
of patients. The International Criteria for Behçet’s Disease (ICBD)
were created in 2006 to overcome this lack of sensitivity. This
classification was revised in 2006. A score ≥ 3 is associated with
sensitivity of 95% and specificity of 90.5% (3). Treatment is based
on chronic immunosuppression with conventional disease-
modifying or targeted biologic drugs such as corticosteroids,
intravenous cyclophosphamide, cyclosporine or anti TNFa
therapy (4). The most recent European League Against
Rheumatism (EULAR) recommendations were updated in 2018
(5). They did not mention autologous hematopoietic stem cell
transplantation (aHSCT), possibly due to limited specific data
in BD.
Over the past 20 years, aHSCT has become a standard of care
for early rapidly progressive Systemic Sclerosis (6–11) and has
emerged as a promising treatment modality for severe Multiple
Sclerosis (12–14) and Crohn’s Disease (12, 15). But patients with
rarer diseases, such as BD, have undergone aHSCT based on
compassionate use.
Led by the Autoimmune Diseases Working Party (ADWP) of
the European Society for Blood and Marrow Transplantation
(EBMT), a previously published retrospective analysis of HSCT
covered all vasculitis (16), in which partial and complete responses
were reported for two patients with BD. Other publications on
autologous stem cell transplantation for BD [without a concomitant
hematologic malignancy, as it has also been reported (17, 18)] only
consist of case reports (19–23). Only one failure with aHSCT in BD
has been reported (22). Further data and composite analysis are
required to inform the balance of benefits and risks of aHSCT in
patients with severe, refractory BD. The aim of this retrospective
study was therefore to bring together a larger experience in order to
describe the efficacy and toxicity of aHSCT in adults with BD
treated in EBMT centers.
METHODS
Study Design
The European Society for Blood and Marrow Transplantation
(EBMT) is a medical and scientific organization that represents
HSCT centers in Europe and worldwide. The EBMT registry
contains details on transplants performed for auto-immune
diseases since 1986, including over 3000 patients undergoing
HSCT for autoimmune diseases. Patients provided written
consent before transplant for the collection and analysis of
anonymized data, and data were maintained in the central EBMT
registry in line with legal and regulatory requirements. This is a
multicenter retrospective study approved by the Autoimmune
Diseases Working Party (ADWP) of the EBMT. Once eligible
patients had been identified from the database, data already held
within EBMT records were sourced and referring centers were
asked to complete a questionnaire to provide further detailed
information regarding patients’ pre- and post-transplant disease
status. All relevant data were collated and held in a specially
designed database within the EBMT. Data from published cases
treated in Europe were extracted from the literature in PubMed and
Science Direct. The algorithm was (“Behcet Syndrome”[Mesh])
AND “Hematopoietic Stem Cell Transplantation”[Mesh] in
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1. Behçet’s disease (BD) diagnosed according to International
Criteria for Behçet’s disease (ICBD) classification criteria
2. Aged 18 years or older at the time of treatment with
autologous stem cell transplantation treated in an EBMT
member center
Exclusion criteria were:
1. aHSCT for a concomitant disease in patients with a diagnosis
of Behcet’s disease
2. Patients with follow-up <6 months
Definitions of Disease Activity
The following definitions of disease activity and response
were used:
• Active disease (persisting or recurring disease activity post-
transplantation, insufficiently controlled by glucocorticoids
and/or disease-modifying drugs).
• Drug-dependent partial response (DDPR) (any documented
clinical and/or laboratory response in patients receiving
glucocorticoids at a dose equivalent or greater than 7.5mg
of prednisolone/day and/or disease-modifying drugs).
• Drug-dependent complete response (DDCR) (no evidence for
disease activity in patients receiving glucocorticoids at a dose
equivalent or greater than 7.5mg of prednisolone/day and/or
disease-modifying drugs)
• Complete remission (CR) (no evidence for disease activity in
patients with glucocorticoids at a dose below 7.5mg of
prednisolone and absence of disease-modifying drugs).
A major relapse was considered in case of involvement of a
life-threatening (pulmonary or vascular event for example) or
functional-threatening organ (which was mainly eye). Other
instances were considered as a minor relapse.
Study Endpoints
Primary endpoint was response to treatment at the last follow-up
visit. Progression was defined as absence of improvement but




• relapse rate, defined as recurrence or new development of
ulcerative disease, ocular lesions or vascular event,
• number of patients in CR, DDPR, DDCR, Active disease at
last follow-up visit,
• toxicities related to aHSCT,
• time to reintroduction or re-escalation of immunosuppressive
treatment,
• Non-Relapse Mortality (NRM) at 100 days and 1 year, defined
as any death following transplant that cannot be attributed to
active disease.
Statistical Method
Due to the low number of patients and the heterogeneity of the
population that do not allow any adjustment, statistics were only
descriptive and no comparison was performed. Categorical
variables were described as numbers and percentage and
continuous variables using median and range.
Data Collection
Cases for inclusion in the study were identified by database queries
in the EBMT Registry according to the abovementioned inclusion
criteria. A letter of invitation to participate in the study was sent to
the EBMT centers. Data were extracted locally retrospectively:
demographic and general data (age at BD onset, sex, age at
aHSCT, ICBD criteria, number of previous therapies before
aHSCT l304 and l306, daily Prednisolone dosage at baseline,
therapies prior to HSCT), mobilization regimen, transplant data
(graft manipulation, stem cell yield and number of collections,
conditioning regimen, Time to engraftment, Adverse event before
100 days), late complications (after day 100), BD status at
mobilization, 6 months, 12 months, and yearly post-aHSCT, date
of most recent follow-up, date of reintroduced immunosuppression
with time-point of reintroduction, relapse or progression, survival
status, cause of death if happened. In case of extraction of the case
from the literature, the same data were collected.
RESULTS
Selection
Nine patients were registered in the EBMT database who all
signed informed consent. Data were available for 8 patients [two
cases were already published but with shorter follow-up (23)].
Two patients were treated in an EBMT center but not reported in
the registry. They were identified from the published literature
(20). All in all, 10 patients were included in our study (Figure 1).
Patient Characteristics
Demographic and clinical characteristics of patients are provided
in Table 1. All patients from EBMT registry had an ICBD score
greater than 4 points. For the 2 patients extracted from the
literature, diagnosis was made according to ISG criteria. Four
patients were female. Median age at the onset of the disease was
24 years (range 9-50y), and median age at the transplantation
was 32 years (range 26-51y). Patients had received median 4
(2-11) previous lines of treatment: 89 % of the patients were
treated with corticosteroids, and 50 % received either
methotrexate, anti-TNFa therapy or cyclophosphamide. All
patients had active disease before aHSCT (one missing data).
Main indications were severe uncontrolled and usually multiple
involvements: ocular (4 patients) gastro-intestinal (4 patients),
neurological (3 patients), cardiac (2 patients), lung and kidney
(1 patient). Aphtosis was not controlled in 4 patients. For one
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patient, indication of transplantation is unknown. Detailed
observations are presented in Table 2.
aHSCT
Cyclophosphamide and Granulocyte-Colony Stimulating
Factor (G-CSF) were administrated during mobilization in 8
patients and G-CSF alone in 1 patient. Data was missing in
1 patient. Conditioning regimen was Melphalan 200mg/m² in 5
patients, BEAM (BCNU-Etoposide-Aracytine-Melphalan) in 3
patients, Cyclophosphamide 200 mg/kg plus Anti-Thymocyte-
Globulin (ATG) in 2 patients. Median follow-up was 48 months
(range 6-252 months). Detailed data are presented in Table 1.
Main Outcome: Response to Treatment
This procedure induced complete remission (CR) in 80%, partial
remission in 10% and lack of response in 10% of the patients.
Relapse rate was 30% (2 relapses in patients in CR and 1 relapse
in the patient in PR) with panuveitis (n=1), aphthosis (n=2) and
arthralgia (n=1) Only one patient did not respond with aHSCT
at 6 months and was treated with allogeneic hematopoietic stem
cell transplantation (HSCT). At the most recent follow-up, 60%
of the patients were in CR without any treatment (including
corticosteroids), three patients relapsed at 24, 37 and 48 months
(Table 2).
Secondary Outcomes
During aHSCT (before day 100), two patients had a fever of
unknown origin, two patients had infectious complications
(pneumonia) and in addition to pneumonia a single patient
had paroxysmal atrial fibrillation, line-associated deep venous
thrombosis and depression. No complications were reported
after Day 100. The patient who did not respond to aHSCT was
treated with allogeneic HSCT. He died three years after
allogeneic transplantation of chronic Graft versus Host Disease
complicated by cytomegalovirus infection. No other late death
was reported. At one year, 8 patients were in CR and one patient
in DDPR. The patient with DDPR had a mild active uveitis. All
other involvements improved (skin, eye, gastro-intestinal,
cardiac, lung, kidney) but sometimes with irreversible organ
damage (decreased visual acuity in patients 1,6,9 and moderate
chronic kidney disease in patient 2). In case of neurological
involvement (3 patients), 2 patients improved but with residual
disability and one patient remained stable. The relapse rate was 3
out 9 (≈ 33%) with only one major relapse. The major
FIGURE 1 | Flow Chart on identification of patients treated with autologous hematopoietic stem cell transplantation for Behçet’s Disease in European Society of
Blood and Marrow Transplantation (EBMT) centers (N=10). *Preliminary results of two patients with shorter follow-up were previously published (23). Long-term
follow-up data are included in this manuscript. †Two cases were already published: De Cata A, Intiso D, Bernal M, et al: Prolonged Remission of Neuro-Behcet
Disease following Autologous Transplantation. Int J Immunopathol Pharmacol 20:91–96, 2007 (center of Foggia).
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involvement was an ocular panuveitis (patient 7) that occurred
48 months after aHSCT leading immediately to introduction of a
new treatment. At last follow-up visit, the patient was in DDCR
with steroids. Two minor relapses with aphthosis (n=2) and
arthralgia (n=1) were reported at 24 and 37 months. Patients
experiencing relapse were treated immediately with steroids and
azathioprine (AZA) or AZA alone. At last follow-up visit, the
patients who relapsed were only treated with AZA and were in
DDCR. One of these patients was resistant to AZA before the
aHSCT and the patient who relapsed with panuveitis was
refractory to steroids before the aHSCT (Table 2).
DISCUSSION
Our study is the first retrospective cohort study conducted in
patients with BD who underwent aHSCT. The results showed a
high rate of efficacy in heavily pretreated patients or in patients
with life-threatening complications with acceptable toxicity
profile and no aHSCT-related mortality. Two patients were in
CR (ie without any treatment) up to 21 years after aHSCT,
raising the question of the efficacy of aHSCT as an effective cure
for patients with BD refractory to multiple conventional
treatments. However, one patient did not respond, one patient
had a major relapse and two patients had a minor relapse
reflecting some limitations of the procedure. Relapses consisted
of the same clinical presentation observed at the onset of the
disease. But there was no life-threatening involvement and all
relapses were controlled by conventional treatments, whereas
patients were refractory to those treatments before aHSCT. This
is consistent with observations following aHSCT in refractory
Crohn’s Disease and use of anti-TNFa therapy after aHSCT (24)
and in rheumatoid arthritis and use of disease-modifying agents
after aHSCT (25), where there is renewed sensitivity to drugs
associated with the “immune reset” after aHSCT.
Such “immune reset” after aHSCT may explain the efficacy in
BD. Although no data are available in BD, this concept is well
described in other auto-immune diseases treated with aHSCT,
and the mechanisms seem to be similar whatever the disease
(26). The destruction of the aberrant immune system leads to
restoration of a new naïve and self-tolerant immune system (27–30).
Renewal of T-cell repertoire is well documented in rheumatic
diseases like systemic sclerosis or systemic lupus erythematosus
with the disappearance of T-cell autoimmune clones (31) and of the
TABLE 1 | Characteristics of the patients and outcomes.
Median (range) or % Missing data
(N=10)
Characteristics of the patients
Sex (Female) 40% (N=4) 0
Age at onset (years) 24 (9-50) 0
Age at transplantation (years) 32 (26-51) 0
Number of previous lines of treatment 4 (2-11) 0
Active disease before mobilization 100% 1
Mobilization 1
Cyclophosphamide + G-CSF 8
G-CSF alone 1
Dose of cyclophosphamide during mobilization 2 (1.5-4) 0
Conditioning regimen 0
Melphalan 200mg/m² 5
Cyclosphosphamide 200 mg/kg –ATG 4.5 mg/kg 2
BEAM 3
Number of days before engraftment showing:
Neutrophils > 0.5 x109/L 11.5 (6-13) 0
Platelets > 50 x109/L 14 (13-20) 1
Complications before Day +100
Fever of Unknown Origin 2 patients/2 episodes
Infectious 2 patients/2 episodes
Other: 1 patient/3 episodes
Atrial Fibrillation, Line associated DVT, Depression





Major Relapse (n=1) 0
Uveitis 1
Minor Relapse (n=2) 0
Aphtosis 2
Arthralgia 1
Median Follow-up (months) 48 (6-252) 0
ATG, Anti Thymocyte Globulin; BEAM, BCNU – Etoposide-Aracytine- Melphalan; CR, Complete Remission: no evidence for disease activity in patients with daily prednisolone equivalent
dosage ≤7.5mg and absence of disease-modifying drugs; DVT, Deep Venous Thrombosis; DDPR, Drug-Dependent Partial Response i.e. any documented clinical and/or laboratory
response in patients receiving glucocorticoids ≥7.5mg daily prednisolone dosage and/or disease-modifying drugs. G-CSF, Granulocyte-colony stimulating factor.
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pre-existing serum auto-antibodies (32). A functional renewal of
regulatory T cells (33) and diversification of the T-cell receptor
(TCR) repertoire (30) are also associated with favorable outcomes in
patients with severe resistant autoimmune and inflammatory
diseases treated with aHSCT (34).
Significantly, our results are congruent with published cases
showing a high rate of efficacy (16, 19–22). By selecting the
patients from EBMT registry with the inclusion of consecutive
patients, this study avoided publication bias, i.e. reporting only
success and not failure. Furthermore, this study is the first
focusing on aHSCT in BD. Other studies had no more than 2
cases as they were focused on primary vasculitis, including BD
among others (16, 22), with shorter follow-up (16, 19–22, 35).
tThis study has limitations including retrospective data
collection (but missing data were rare, and they pertained to
secondary data) and possible under-reporting of aHSCT for BD
in the EBMT registry (the 2 cases extracted from the literature
illustrate this issue (20), despite the obligation of full EBMT
TABLE 2 | Individual characteristics and outcome for patients with Behçet’s disease treated with autologous stem cell transplantation in European Society of Blood and
Marrow Transplantation centers (N=10).
a) Before transplantation








1 Trieste F 29 G,O, Oc, V, GI TS, SC, CSA, AZA Active G, O, Oc, V, GI
2 Heidelberg M 48 G,O, Oc, V, N,
K, L
SC, iCYC, oCYC Active G, O, Oc, K, L
3 Heidelberg M 25 G,O, S, V, CI SC, MTX Active G, O, Oc, CI
4 Foggia M 22 N* SC, CLB Active N
5 Foggia M 23 N* SC, CLB Active N
6 Genova F 20 G,O, Oc, S, A,
N, GI
TS, SC, iCYC, Active N, GI
7 Sydney F 16 G,O, Oc, S SC, MTX, IFN, IFX, RTX, PYX, oCYC,
CSA, TCZ
Active Oc
8 Liverpool M 24 G,O, Oc, S, V SC, MTX, IFX, iCYC, TCL, MMF, ETN Unknown Unknown
9 Liverpool F 9 G,O, S, P , A, GI TS, SC, COL, DAP, MTX, IFX, ADA, ATZ,
AZA, LF, ETN
Active O, GI
10 Liverpool M 50 G,O, S, V, A, N,
GI, CI
IFN, ATZ, AZA, MMF, ETN, CTZ Active V, GI, CI
*patients extracted from the literature, fulfilling International Study Group criteria of Behcet’s Disease. A, Arthritis; ADA, Adalimumab; ATZ, Alemtuzumab; AZA, Aziathoprine; CI, Cardiac
Involvement; CLB, Chlorambucil; COL, Colchicine; CSA, Cyclosporine; CTZ, Certolizumab; DAP, Dapsone; ETN, Etanercept; FU, Follow-up; iCYC. intravenous Cyclophosphamide; IFX,
Infliximab; IFN, Interferon alpha; G, Genital aphtosis; GI, Gastro-Intestinal Involvement; K, Kidney; L, Lung; LF, Leflunomide; MMF, Mycophenolate Mofetil; MTX, Methotrexate; N,
Neurological involvement; O, Oral aphtosis; Oc, Ocular involvement; oCYC, Oral Cyclophosphamide; P, Pathergy test positive; PYX, Pentoxifylline; RTX, Rituximab; S, Skin involvement
(skin ulcer or erythema nodosum); SC, Systemic Corticoids; TCL, Tacrolimus; TCZ, Tocilizumab; TS, Topical Steroids.
TABLE 2B |











(FU reported in months)
1 1999 33 G-CSF iCYC+ATG CR 48 No
2 1999 49 iCYC + G-CSF Melphalan Fever of unknown origin CR 252 Yes (96)
3 1999 31 iCYC + G-CSF Melphalan Fever of unknown origin CR 252 Yes (72)
4 Before
2002
26 iCYC + G-CSF BEAM CR 48 Yes (48)
5 Before
2002
26 iCYC + G-CSF BEAM CR 48 Yes (48)
6 2002 30 iCYC + G-CSF BEAM NR 6 No
7 2011 49 iCYC + G-CSF iCYC+ATG DDPR* 48 No
8 2009 29 iCYC + G-CSF Melphalan CR* 24 No




10 2016 51 iCYC + G-CSF Melphalan Pneumonia CR 96 No
*Relapse.
AF, Atrial Fibrillation; ATG, Anti Thymocyte Globulin; BEAM, Bicnu, Etoposide, Aracytine, Melphalan; CR, Complete Remission: no evidence for disease activity in patients with daily
prednisolone equivalent dosage ≤ 7.5mg and absence of disease-modifying drugs; DDPR, Drug- Dependent Partial Response = any documented clinical and/or laboratory response in
patients receiving glucocorticoids ≥7.5mg daily prednisolone dosage and/or disease modifying drugs; DVT, Deep Venous Thrombosis; iCYC, intravenous Cyclophosphamide; G-CSF,
Granular Colony Stimulating Factor; NR, No Response; OR, Overall Response.
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member centers to report all cases). This bias is likely to be
independent from aHSCT outcome. The literature search
improved sensitivity but may have been affected by publication
bias. Another bias was the heterogeneity of patients characteristics
at baseline (especially in terms of organ involvements), reflecting
the absence of consensus or guidelines on the indication of aHSCT
in BD. The long term risk/benefit balance of aHSCT in BD should
be evaluated in prospective studies, ideally randomized controlled
trials of anti-TNFa therapy refractory patients against other
standard of care. But it would be unlikely to be feasible due to
the rare incidence of patients with this severity of BD. More
pragmatically, ongoing registry-based analyses may help to define
the role of aHSCT in BD and further inform transplant technique
and patient selection to optimize patient outcomes.
In conclusion, based on our data, aHSCT has an acceptable
safety profile and represents a feasible and relatively effective
procedure in severe and conventional treatment-resistant cases
of BD. It should be considered as a treatment option for patients
refractory to anti-TNFa with high disease burden. Further data
ideally from randomized controlled trials are warranted.
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